CareDx (CDNA) Tops Q1 EPS by 21c; Withdraws Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to CareDx (CDNA) Tops Q1 EPS by 21c; Withdraws Guidance
May 10, 2023 4:05 PM EDT
BRISBANE, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today reported financial results for the first quarter ended March 31, 2023.
First Quarter 2023 Highlights
Delivered record number of patient test results for AlloMap® and AlloSure® of approximately 49,900 tests, growing year-over-year by 17%, and exceeding year-over-year market growth of 10%.
Reported revenue of $77.3 million, a decrease of 3% year-over year. This excludes approximately $8.9 million in revenue associated with...
More
May 8, 2023 7:01 AM EDT
BRISBANE, Calif.--(BUSINESS WIRE)--
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 10,... More
